IL102410A - Pharmaceutical preparation containing a combination of extracts of Corridlis and Eshulation - Google Patents
Pharmaceutical preparation containing a combination of extracts of Corridlis and EshulationInfo
- Publication number
- IL102410A IL102410A IL102410A IL10241092A IL102410A IL 102410 A IL102410 A IL 102410A IL 102410 A IL102410 A IL 102410A IL 10241092 A IL10241092 A IL 10241092A IL 102410 A IL102410 A IL 102410A
- Authority
- IL
- Israel
- Prior art keywords
- corydalis
- eschscholtzia
- extract
- pharmaceutical composition
- extracts
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 115
- 241000218176 Corydalis Species 0.000 title claims abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000000605 extraction Methods 0.000 claims abstract description 17
- 238000013019 agitation Methods 0.000 claims abstract description 11
- 206010029216 Nervousness Diseases 0.000 claims abstract description 9
- 230000004064 dysfunction Effects 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 34
- 229960003638 dopamine Drugs 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 230000004060 metabolic process Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 5
- 206010034010 Parkinsonism Diseases 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims 3
- 150000001298 alcohols Chemical class 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 description 58
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 32
- 230000000694 effects Effects 0.000 description 26
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 102000003425 Tyrosinase Human genes 0.000 description 14
- 108060008724 Tyrosinase Proteins 0.000 description 14
- WTDRDQBEARUVNC-UHFFFAOYSA-N dopa Chemical compound OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 238000011835 investigation Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 8
- 229940102884 adrenalin Drugs 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 8
- 239000011668 ascorbic acid Substances 0.000 description 8
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 238000005805 hydroxylation reaction Methods 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 150000003943 catecholamines Chemical class 0.000 description 5
- 150000002009 diols Chemical class 0.000 description 5
- 230000033444 hydroxylation Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229940098465 tincture Drugs 0.000 description 4
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000006701 autoxidation reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-Dihydroxybenzaldehyde Natural products OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 108040001319 catechol oxidase activity proteins Proteins 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940114166 dl dopa Drugs 0.000 description 2
- 108700006189 dopamine beta hydroxylase deficiency Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000004313 potentiometry Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960003732 tyramine Drugs 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- MGBKJKDRMRAZKC-UHFFFAOYSA-N 3-aminobenzene-1,2-diol Chemical compound NC1=CC=CC(O)=C1O MGBKJKDRMRAZKC-UHFFFAOYSA-N 0.000 description 1
- ATTTYDOGGQCDDK-UHFFFAOYSA-N C1=CC2=CC(=O)C(=O)NC2=C2C=CN=C21 Chemical compound C1=CC2=CC(=O)C(=O)NC2=C2C=CN=C21 ATTTYDOGGQCDDK-UHFFFAOYSA-N 0.000 description 1
- 241001576541 Corydalis cava Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 235000006629 Prosopis spicigera Nutrition 0.000 description 1
- 240000000037 Prosopis spicigera Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- PUTCXBJUWNRWJH-UHFFFAOYSA-N cyclohexa-3,5-diene-1,1,2-triol Chemical compound OC1C=CC=CC1(O)O PUTCXBJUWNRWJH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- QZMUBZJJJKIXKV-UHFFFAOYSA-N pyrroloquinoline quinol Chemical compound N1=C(C(O)=O)C=C(C(O)=O)C2=C(NC(C(=O)O)=C3)C3=C(O)C(O)=C21 QZMUBZJJJKIXKV-UHFFFAOYSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/50—Fumariaceae (Fumitory family), e.g. bleeding heart
- A61K36/505—Corydalis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4122706A DE4122706C1 (enExample) | 1991-07-09 | 1991-07-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL102410A0 IL102410A0 (en) | 1993-01-14 |
| IL102410A true IL102410A (en) | 1998-02-22 |
Family
ID=6435763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL102410A IL102410A (en) | 1991-07-09 | 1992-07-03 | Pharmaceutical preparation containing a combination of extracts of Corridlis and Eshulation |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5308619A (enExample) |
| EP (1) | EP0535317B1 (enExample) |
| JP (1) | JPH085796B2 (enExample) |
| KR (1) | KR100225010B1 (enExample) |
| AT (1) | ATE139446T1 (enExample) |
| AU (1) | AU652262B2 (enExample) |
| CA (1) | CA2072950A1 (enExample) |
| CZ (1) | CZ279915B6 (enExample) |
| DE (2) | DE4122706C1 (enExample) |
| DK (1) | DK0535317T3 (enExample) |
| EE (1) | EE03169B1 (enExample) |
| EG (1) | EG20140A (enExample) |
| ES (1) | ES2088053T3 (enExample) |
| GR (1) | GR3020289T3 (enExample) |
| HU (1) | HUT61668A (enExample) |
| IE (1) | IE74691B1 (enExample) |
| IL (1) | IL102410A (enExample) |
| MD (1) | MD1139G2 (enExample) |
| MX (1) | MX9204011A (enExample) |
| PT (1) | PT100668B (enExample) |
| RU (1) | RU2072859C1 (enExample) |
| SI (1) | SI9200138A (enExample) |
| SK (1) | SK279531B6 (enExample) |
| UA (1) | UA26971C2 (enExample) |
| YU (1) | YU48554B (enExample) |
| ZA (1) | ZA925059B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5460819A (en) * | 1991-12-13 | 1995-10-24 | Children's Medical Center Corporation | Method for treating PQQ-responsive heavy metal toxicity |
| FR2743721B1 (fr) * | 1996-01-19 | 1998-04-03 | Innothera Lab Sa | Association mineralo-phytotherapique sous forme galenique unitaire de comprimes |
| PT1066042E (pt) * | 1998-03-26 | 2006-12-29 | Phytopharm Plc | Saponinas esteroides para o tratamento de doença de alzheimer |
| NZ514253A (en) | 1999-03-11 | 2003-06-30 | Zeachem Inc | Process for producing ethanol |
| US7074603B2 (en) * | 1999-03-11 | 2006-07-11 | Zeachem, Inc. | Process for producing ethanol from corn dry milling |
| US6521634B2 (en) | 2001-03-28 | 2003-02-18 | The Hong Kong University Of Science & Technology | Uses of dl-THP |
| KR20030063735A (ko) * | 2002-01-23 | 2003-07-31 | 주식회사 석산터메디칼 | 신경성 질환 예방 및 치료를 위한 약제학적 조성물 및,실험용 동물에 신경성 질환을 일으키는 방법 |
| US7341745B2 (en) * | 2003-02-07 | 2008-03-11 | Arizona Health Consulting, Llc | Method for decreasing nicotine and other substance use in humans |
| NZ586246A (en) * | 2004-01-29 | 2013-03-28 | Zeachem Inc | Recovery of organic acids from a fermentation broth |
| FR2878163B1 (fr) * | 2004-11-25 | 2007-04-27 | R & D Pharma | Nouvelles compositions pharmaceutiques a visee phytotherapeutique |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR961M (enExample) * | 1961-03-03 | 1961-11-27 | ||
| DE1467868A1 (de) * | 1964-10-20 | 1969-01-30 | Dainippon Pharmaceutical Co | Verfahren zur Herstellung eines gegen Geschwuere des Verdauungstraktes wirksamen Medikamentes |
| JPS60181023A (ja) * | 1984-02-28 | 1985-09-14 | Nitto Electric Ind Co Ltd | 漢方局所麻酔性組成物 |
-
1991
- 1991-07-09 DE DE4122706A patent/DE4122706C1/de not_active Expired - Fee Related
-
1992
- 1992-07-02 AU AU19370/92A patent/AU652262B2/en not_active Ceased
- 1992-07-02 CA CA002072950A patent/CA2072950A1/en not_active Abandoned
- 1992-07-03 IL IL102410A patent/IL102410A/en not_active IP Right Cessation
- 1992-07-06 YU YU67492A patent/YU48554B/sh unknown
- 1992-07-07 US US07/909,675 patent/US5308619A/en not_active Expired - Fee Related
- 1992-07-07 ZA ZA925059A patent/ZA925059B/xx unknown
- 1992-07-08 SI SI19929200138A patent/SI9200138A/sl unknown
- 1992-07-08 EG EG37092A patent/EG20140A/xx active
- 1992-07-08 KR KR1019920012112A patent/KR100225010B1/ko not_active Expired - Fee Related
- 1992-07-08 PT PT100668A patent/PT100668B/pt not_active IP Right Cessation
- 1992-07-08 RU SU925052267A patent/RU2072859C1/ru active
- 1992-07-08 IE IE922226A patent/IE74691B1/en not_active IP Right Cessation
- 1992-07-08 MX MX9204011A patent/MX9204011A/es not_active IP Right Cessation
- 1992-07-09 JP JP4182626A patent/JPH085796B2/ja not_active Expired - Lifetime
- 1992-07-09 CZ CS922143A patent/CZ279915B6/cs not_active IP Right Cessation
- 1992-07-09 ES ES92111709T patent/ES2088053T3/es not_active Expired - Lifetime
- 1992-07-09 SK SK2143-92A patent/SK279531B6/sk unknown
- 1992-07-09 HU HU9202274A patent/HUT61668A/hu unknown
- 1992-07-09 AT AT92111709T patent/ATE139446T1/de not_active IP Right Cessation
- 1992-07-09 DK DK92111709.9T patent/DK0535317T3/da active
- 1992-07-09 EP EP92111709A patent/EP0535317B1/de not_active Expired - Lifetime
- 1992-07-09 DE DE59206608T patent/DE59206608D1/de not_active Expired - Fee Related
-
1993
- 1993-03-12 UA UA93002403A patent/UA26971C2/uk unknown
-
1994
- 1994-08-09 EE EE9400046A patent/EE03169B1/xx unknown
- 1994-12-30 MD MD95-0171A patent/MD1139G2/ro unknown
-
1996
- 1996-06-20 GR GR960401185T patent/GR3020289T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11331363B2 (en) | Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations | |
| US6936283B2 (en) | Composition for stimulation of specific metallo-enzymes | |
| US5308619A (en) | Pharmaceutical and its use for the treatment of states of agitation and nervous dysfunctions | |
| CN114867863A (zh) | 基于含氮天然物质的发酵的一氧化氮代谢组的固定化及稳定化方法 | |
| Hashim Fauzy et al. | Piper sarmentosum leaves aqueous extract attenuates vascular endothelial dysfunction in spontaneously hypertensive rats | |
| Soterakis et al. | Increased rate of alcohol removal from blood with oral fructose and sucrose | |
| KR100661132B1 (ko) | 숙취 해소용 조성물 및 이의 제조 방법 | |
| KR102569055B1 (ko) | 아세트알데하이드 독성을 감소시키기 위한 베타-에스신을 포함하는 경구 조성물 | |
| KR100512912B1 (ko) | 알코올대사 생약 촉진제 | |
| AU2021201581B2 (en) | Use of antrodia cinnamomea for increasing alcohol metabolism or/and hangover | |
| KR20040047617A (ko) | 니코틴제거 효과가 있는 조성물 및 그 제조 방법 | |
| LT3355B (en) | Pharmaceutical and its use for the treatment of states of agitation and nerve dysfunctions | |
| Esan et al. | The Effects of okra (Abelmoschus esculentus (L) M oench) fruit extracts on diabetes markers in streptozotocin-induced diabetic rats. Arch | |
| KR102885707B1 (ko) | 미나리 아임계 수 추출물을 유효성분으로 포함하는 숙취해소용 조성물 | |
| Srivastava et al. | Hypoglycemic effect of polyherbal formulations in alloxan induced diabetic mice | |
| SPER et al. | En zy matic spec tro pho tomet ric de ter mi na tion of solu ble ox alate con tent in some mul ti herbal func tional prod ucts re duc ing stress re lated health dis or ders | |
| HK40015220B (en) | Oral compositions comprising beta-escin and chokeberry juice for reducing acetaldehyde toxicity | |
| HK40015220A (en) | Oral compositions comprising beta-escin and chokeberry juice for reducing acetaldehyde toxicity | |
| EP3357541A1 (en) | Methylsulfonylmethane composition for reducing blood alcohol content | |
| MXPA97003308A (en) | Medical composition for diabe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |